title: TREMFYA® (guselkumab) is first and only IL-23 inhibitor to demonstrate sustained clinical and endoscopic outcomes with a fully subcutaneous regimen through 48 weeks in ulcerative colitis
source: Yahoo
date: 2025-10-07
url: https://finnhub.io/api/news?id=d55f5c0dce3d962221b8f469a395beb0ba2909ca6e46b49a6b2d938931ce6c73
Johnson & Johnson (NYSE: JNJ) today announced new 48-week data from the Phase 3 ASTRO study evaluating TREMFYA® (guselkumab) subcutaneous (SC) induction and maintenance therapy in adults with moderately to severely active ulcerative colitis (UC). These data show clinically meaningful rates of clinical and endoscopic remission, making TREMFYA® the first and only IL-23 inhibitor to demonstrate robust results with a fully SC regimen.1 The findings are among 20 Johnson & Johnson abstracts being pres
